106 related articles for article (PubMed ID: 36660018)
1. Erratum to "lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2".
Mao W; Wang S; Chen R; He Y; Lu R; Zheng M
Open Med (Wars); 2022; 17(1):2138-2139. PubMed ID: 36660018
[TBL] [Abstract][Full Text] [Related]
2. lncRNA NORAD promotes lung cancer progression by competitively binding to miR-28-3p with E2F2.
Mao W; Wang S; Chen R; He Y; Lu R; Zheng M
Open Med (Wars); 2022; 17(1):1538-1549. PubMed ID: 36245705
[TBL] [Abstract][Full Text] [Related]
3. LncRNA NORAD, sponging miR-363-3p, promotes invasion and EMT by upregulating PEAK1 and activating the ERK signaling pathway in NSCLC cells.
Geng Q; Li Z; Li X; Wu Y; Chen N
J Bioenerg Biomembr; 2021 Jun; 53(3):321-332. PubMed ID: 33742335
[TBL] [Abstract][Full Text] [Related]
4. lncRNA NORAD promotes hepatocellular carcinoma progression via regulating miR-144-3p/SEPT2.
Tian Q; Yan X; Yang L; Liu Z; Yuan Z; Shen Z; Zhang Y
Am J Transl Res; 2020; 12(5):2257-2266. PubMed ID: 32509217
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA NORAD promotes the occurrence and development of non-small cell lung cancer by adsorbing MiR-656-3p.
Chen T; Qin S; Gu Y; Pan H; Bian D
Mol Genet Genomic Med; 2019 Aug; 7(8):e757. PubMed ID: 31207175
[TBL] [Abstract][Full Text] [Related]
6. LncRNA NORAD Mediates the Proliferation and Apoptosis of Diffuse Large-B-Cell Lymphoma via Regulation of miR-345-3p/TRAF6 Axis.
Li Y; Lv Y; Wang J; Zhu X; Chen J; Zhang W; Wang C; Jiang L
Arch Med Res; 2022 Apr; 53(3):271-279. PubMed ID: 35164979
[TBL] [Abstract][Full Text] [Related]
7. Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p.
Xu C; Zhu LX; Sun DM; Yao H; Han DX
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1672-1681. PubMed ID: 32141533
[TBL] [Abstract][Full Text] [Related]
8. LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma.
Xie X; Liu W; Duan Z; Li X; Zhang L; Yang G
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):143-148. PubMed ID: 32538761
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA NORAD exhaustion represses prostate cancer progression through inhibiting TRIP13 expression via competitively binding to miR-495-3p.
Chen F; Liu L; Wang S
Cancer Cell Int; 2020; 20():323. PubMed ID: 32694945
[TBL] [Abstract][Full Text] [Related]
10. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
Wang B; Xu L; Zhang J; Cheng X; Xu Q; Wang J; Mao F
Biomed Pharmacother; 2020 Sep; 129():110268. PubMed ID: 32563146
[TBL] [Abstract][Full Text] [Related]
11. LncRNA NORAD stimulates proliferation and migration of renal cancer via activating the miR-144-3p/MYCN axis.
Zhao W; Wang L; Xu F
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10426-10432. PubMed ID: 33155199
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA NORAD promotes pancreatic cancer stem cell proliferation and self-renewal by blocking microRNA-202-5p-mediated ANP32E inhibition.
Ma YS; Yang XL; Liu YS; Ding H; Wu JJ; Shi Y; Jia CY; Lu GX; Zhang DD; Wang HM; Wang PY; Yu F; Lv ZW; Wang GR; Liu JB; Fu D
J Transl Med; 2021 Sep; 19(1):400. PubMed ID: 34551785
[TBL] [Abstract][Full Text] [Related]
13. LncRNA ZEB1-AS1 reduces liver cancer cell proliferation by targeting miR-365a-3p.
Li M; Guan H; Liu Y; Gan X
Exp Ther Med; 2019 May; 17(5):3539-3547. PubMed ID: 30988735
[TBL] [Abstract][Full Text] [Related]
14. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α).
Zhang L; Wu H; Zhang Y; Xiao X; Chu F; Zhang L
Bioengineered; 2022 Jan; 13(1):950-962. PubMed ID: 34969360
[TBL] [Abstract][Full Text] [Related]
15. BMSC-EV-derived lncRNA NORAD Facilitates Migration, Invasion, and Angiogenesis in Osteosarcoma Cells by Regulating CREBBP
Feng D; Li Z; Yang L; Liang H; He H; Liu L; Zhang W
Oxid Med Cell Longev; 2022; 2022():8825784. PubMed ID: 35281474
[TBL] [Abstract][Full Text] [Related]
16. LncRNA NORAD promotes thyroid carcinoma progression by targeting miR-451.
Shi L; Cong YZ; Wang ZJ
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(20):6187-6195. PubMed ID: 34730199
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of the Serum lncRNA NORAD Expression in Patients with Neonatal Sepsis and Its Association with miR-410-3p.
Zhang H; Li L; Xu L; Zheng Y
J Inflamm Res; 2021; 14():4181-4188. PubMed ID: 34471374
[TBL] [Abstract][Full Text] [Related]
18. Non-coding RNA Activated by DNA Damage: Review of Its Roles in the Carcinogenesis.
Ghafouri-Fard S; Azimi T; Hussen BM; Abak A; Taheri M; Dilmaghani NA
Front Cell Dev Biol; 2021; 9():714787. PubMed ID: 34485302
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA-non-coding RNA activated by DNA damage inhibition suppresses hepatic stellate cell activation via microRNA-495-3p/sphingosine 1-phosphate receptor 3 axis.
Zou L; Shi C; Wang D; Cheng J; Wang Q; Wang L; Yang G
Bioengineered; 2022 Mar; 13(3):6150-6162. PubMed ID: 35200103
[TBL] [Abstract][Full Text] [Related]
20. LncRNA NORAD promotes thyroid carcinoma progression through targeting miR-202-5p.
He H; Yang H; Liu D; Pei R
Am J Transl Res; 2019; 11(1):290-299. PubMed ID: 30787987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
